Insider trade

Gilead Sciences (GILD): Director sold ~$357K

Kelly A. Kramer, Director at Gilead Sciences, sold ~$357K of Gilead Sciences shares.

~$357K
Approx. value · 2,806 sh @ $127.11
1,339
Holds after · shares reported
Traded
Nov 26, 2025
Filed
Dec 1, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 23, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
  2. Sep 29, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  3. Oct 15, 2025Insider · 2 peopleInsiders: 2 sales (~$649K)
  4. Oct 28, 2025Insider · 1 personInsiders: 2 sales (~$1.2M)
  5. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  6. Nov 12, 2025Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 17 employees
  7. Nov 12, 2025Insider · 1 personInsiders: 3 sales (~$6.6M)
  8. Nov 15, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025.”
  9. Nov 17, 2025Insider · 2 peopleInsiders: 3 sales (~$3.8M)
  10. Nov 26, 2025 · this disclosureInsiderDirector sold ~$357K of GILD shares in the open market

What came next

  1. Nov 28, 2025Insider · 3 peopleInsiders: 4 sales (~$2.2M)
  2. Dec 12, 2025Government · Federal Register noticeDetermination That DEMEROL (Meperidine Hydrochloride) Tablet, 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  3. Dec 15, 2025Insider · 2 peopleInsiders: 2 sales (~$732K)
  4. Dec 29, 2025InsiderCEO sold ~$1.25M of GILD shares in the open market
  5. Jan 15, 2026Insider · 2 peopleInsiders: 2 sales (~$746K)
  6. Jan 20, 2026InsiderDirector sold ~$618K of GILD shares in the open market
  7. Jan 21, 2026Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 34 employees
  8. Jan 23, 2026InsiderCEO sold ~$15.6M of GILD shares in the open market
  9. Jan 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  10. Jan 28, 2026Insider · 1 personInsiders: 2 sales (~$1.4M)
  11. Feb 5, 20265% stakeFMR LLC reported a passive stake (13G) of 5.3%
  12. Feb 5, 2026InsiderCEO sold ~$17.3M of GILD shares in the open market
  13. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
  14. Feb 17, 2026Insider · 2 peopleInsiders: 4 sales (~$4.8M)
  15. Feb 22, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  16. Feb 27, 2026Insider · 1 personInsiders: 3 sales (~$1.4M)
  17. Mar 16, 2026Insider · 2 peopleInsiders: 2 sales (~$865K)
  18. Mar 25, 2026Layoff notice · 333 Lakeside Drive San Mateo CA 94404Layoff notice filed in CA: 51 employees
  19. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Kelly A. Kramer, Director

The full history of Kelly A. Kramer, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Gilead Sciences (GILD) insider traded, and how much?

Kelly A. Kramer, Director at Gilead Sciences, sold ~$357K of Gilead Sciences shares. 2,806 shares at $127.11.

When did it happen, and when was it made public?

Traded: Nov 26, 2025. Filed: Dec 1, 2025. That is 5 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Gilead Sciences recently?

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.

Does this mean GILD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data